



PDC*LINE PHARMA TO ATTEND UPCOMING SCIENTIFIC AND PARTNERING CONFERENCES THIS FALL

Liège, Belgium and Grenoble, France, October 20, 2020 – PDC*line Pharma, a biotech company developing a novel class of potent and off-the-shelf cancer immunotherapies to treat cancer patients, today announced that the Company will give presentations and attend to the following scientific and partnering conferences in Europe and US:

World Vaccine Congress Europe

Date: October 14-21, 2020

Presenter/attendance: Eric Halioua, CEO

Venue : Virtual event

Cell & Gene Strategy Meeting 2020

Date: October 22, 2020

Presenter/attendance: Eric Halioua, CEO

Venue: Virtual event

BIO-Europe

Date: October 26-20, 2020

Presenter/attendance: Eric Halioua, CEO and Laurent Levy, COO/CFO

Venue: Virtual event

World Immunotherapy Congress

Date: November 2-5, 2020

Presenter/attendance: Eric Halioua, CEO and Laurent Levy, COO/CFO

Venue: Virtual event

Neoantigen Based Therapies Summit 2020

Date: November 3-5, 2020

Presenter/attendance: Eric Halioua, CEO and Laurent Levy, COO/CFO

Venue: Virtual event

7th China Healthcare Summit

Date: November 9-13, 2020

Presenter/attendance: Eric Halioua, CEO and Laurent Levy, COO/CFO

Venue: Virtual event



About PDC*line Pharma's technology

PDC*line's biological features provide unique advantages:

- A professional antigen-presenting cell line, much more potent than conventional dendritic cells in priming and expanding antitumor-specific cytotoxic CD8+ T cells (conventional tumor antigens and neoantigens)
- While allogeneic, PDC*line is not rejected by the host immune system and can be injected several times to boost the immune response
- Easily produced on a large scale, with a fully mastered and simple manufacturing process (use of bioreactors with a synthetic medium without growth, differentiation or activation factors)
- Easy to use: after thawing, the same off-the-shelf product is used to treat the whole target population with a cancer type expressing the target antigens
- Very versatile: tumor antigens can be provided by peptide loading, mRNA transfection or retrovirus transduction of PDC*line and the target population can be extended beyond HLA-A2 (currently used as it is expressed by 50% of the Caucasian population) by using other HLAs, either already expressed by PDC*line or added by genetic modification. Moreover, new candidates can be validated for new cancer indications in a few weeks, with *ex vivo* testing using human peripheral blood mononuclear cells (PBMC)
- Synergizes with anti-PD-1 to activate antitumor CD8 T cells

About PDC*line Pharma

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of plasmacytoid dendritic cells (PDC*line). PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC*line Pharma focuses on the development of PDC*lung01, a candidate for non-small-cell lung cancer (NSCLC) currently in phase I/II trials, and PDC*neo with neoantigens in preclinical development. The company has a staff of 25, with an experienced management team. In March 2019, PDC*line Pharma granted an exclusive license to the LG Chem Life Sciences company in South Korea and an exclusive option in other Asian countries, for the development and commercialization of the PDC*lung01 cancer vaccine for lung cancer. The total deal is worth \$123M, plus tiered royalties on net sales in Asia.

www.pdc-line-pharma.com

Media and analysts contact
Andrew Lloyd & Associates
Jo Reeder - Juliette Schmitt-dos Santos
jo@ala.com / juliette@ala.com
UK: + 44 1273 675 100
[@ALA_Group](#)
